Robert Doebele is an Oncology physician affiliated with University of Colorado Cancer Center. OpenAlex indexes 532 publications with 31,913 citations (h-index 74); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 19 Nov 2012.
Clinical trials
- Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Sponsor: Boundless Bio, Inc.
- Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
Sponsor: Boundless Bio, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
2 NIH research awards on record, funded 2016–2020 per NIH RePORTER. The latest:
- The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.
University of Colorado Denver
FY2020$349,477R01CA193935 - The role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.
University of Colorado Denver
FY2019$338,993R01CA193935
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
JTO Clinical and Research Reports
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Antonio Jimeno, MD
University of Colorado Cancer Center
Wells Messersmith, MD
University of Colorado Cancer Center
Manali Kamdar, MD
University of Colorado Cancer Center
Richard Schulick, MD, MBA
University of Colorado Cancer Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”